

Atopic Dermatitis Patient Enrollment and Prescription Form

P: 1-844-443-6879 F: 1-844-329-2447

ePrescribe to our pharmacy at "GENTRY HEALTH SERVICES" in Avon Lake, Ohio.

PATIENT INFORMATION

Patient Name _____
 DOB ___/___/___ SSN _____ Gender _____
 Weight _____ Height _____ Phone _____
 Address _____
 City, State, Zip _____
 Cell Phone _____ E-Mail _____
PLEASE PROVIDE COPY OF PATIENT'S PRESCRIPTION INSURANCE CARD WITH ENROLLMENT FORM
 Insurance Co. Name _____
 Insurance Co. Phone _____ Group# _____
 Policy Holder Name _____
 Policy Holder Employer _____
 Relationship to Patient _____
 ID# _____ RxBIN _____ PCN _____

PRESCRIBER INFORMATION

Prescriber's Name _____
 Practice Name _____
 DEA _____ NPI _____
 Address _____
 City, State, Zip _____
 Phone _____ Fax _____
 Office Contact Person _____
 Office Contact EMAIL _____
 Prescription Date _____ Date Needed _____


With my signature on this form, I also authorize use of Gentry Health's Services which includes serving as my prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.
Prescriber Signature _____

Ship to: Patient Prescriber's Office Discount Drug Mart

PLEASE PROVIDE ALL RELEVANT CHART NOTES FOR INSURANCE PURPOSES

Medical Information (DO NOT COMPLETE IF CHART NOTES ARE PROVIDED)

Diagnosis _____ ICD-10 Code _____
 Date of Diagnosis _____ Body Surface Affected: _____ %
 Patient has moderate to severe atopic dermatitis (AD) that is inadequately controlled on prior or current topical therapy
 Drug Allergies _____ Latex Allergy? YES NO
 Failed Prior therapies?
 Topical Corticosteroids:
 _____ to _____
 _____ to _____
 Topical therapy not appropriate
 Reason: _____
 Systemic Corticosteroids, Immunosuppressants and/or Phototherapy:
 _____ to _____
 _____ to _____
 _____ to _____
 Systemic corticosteroids not appropriate
 Immunosuppressants not appropriate
 Phototherapy not appropriate
 Reason: _____
 Does the patient have history of conjunctivitis or keratitis? YES NO
 Additional Comments _____



Affected Areas: Hands Feet
 Scalp Groin Nails Face
 Other: _____

PRESCRIPTION INFORMATION

(please indicate days supply if different than suggested days supply)

Adbry® (tralokinumab-ldrm) 150mg Pre-filled Syringe 300 mg Auto-Injector
 ADULT DOSING: 600MG SQ at week 0 and 300MG every other week Quantity: _____ Refills _____
 PEDIATRIC DOSING: 300MG at week 0 and 150MG every other week Quantity: _____ Refills _____

Cibinqo™ (abrocitinib) 50mg Tablet 100 mg Tablet 200 mg Tablet
 Directions: Take 1 tablet daily Qty: 30 tablets Refills _____

Dupixent® (dupilumab) Syringe Pen
 ADULT STARTER: 600MG SQ at week 0, 300MG SQ at weeks 2 & 4 Quantity: 4 Refills _____
 ADULT MAINTENANCE: 300MG SQ once every 2 weeks Quantity: 2 Refills _____
 PED (up to 5yr): 200MG SQ every 4 weeks Quantity: 2 Refills _____
 PED (up to 5yr): 300MG SQ every 4 weeks Quantity: 2 Refills _____
 PED (6-17 yrs) up to 30kg: 600MG SQ week 0, 300mg Q4 weeks Quantity: 2 Refills _____
 PED (6-17 yrs) up to 60kg: 400MG SQ week 0, 200mg Q2 weeks Quantity: 2 Refills _____
 PED (6-17 yrs) above 60kg: 600MG SQ week 0, 300mg Q2 weeks Quantity: 2 Refills _____

OPZELURA™ 1.5% Cream 60 GM Tube
 Directions: Apply thin layer twice daily to affected areas (up to 20% BSA) MAX 60 gm/wk. Qty: _____ tube(s) Refills _____

Rinvoq® (upadacitinib) 15mg ER Tablet 30mg ER Tablet
 Directions: Take 1 tablet daily Qty: 30 tablets Refills _____

CONFIDENTIALITY NOTICE: THE INFORMATION IN THIS TRANSMITTAL IS CONFIDENTIAL AND INTENDED ONLY FOR THE RECIPIENT LISTED ABOVE. IF YOU ARE NEITHER THE INTENDED RECIPIENT NOR A PERSON RESPONSIBLE FOR DELIVERING THIS TRANSMITTAL TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISTRIBUTION OR COPYING OF THIS TRANSMITTAL IS PROHIBITED. IF YOU RECEIVE THIS TRANSMITTAL IN ERROR, PLEASE IMMEDIATELY NOTIFY US AND RETURN THE TRANSMITTAL TO US AT OUR EXPENSE.